Cited by 140Adipokines, Inflammation, and Metabolic DiseasesCardiovascular Disease and AdiposityAdipose Tissue and Metabolism

Relationship of Adiponectin with Markers of Systemic Inflammation, Atherogenic Dyslipidemia, and Heart Failure in Patients with Coronary Heart Disease

von Eynatten, Maximilian, Hamann, Andreas, Twardella, Dorothee, Nawroth, Peter P, Brenner, Hermann, Rothenbacher, Dietrich·2006·Clinical Chemistry

Abstract

Background: Adiponectin, an adipocyte-derived hormone, appears to be a modulator of lipid metabolism and systemic inflammation and is present in particularly low concentrations in patients with coronary heart disease (CHD). However, the clinical importance of adiponectin in individuals at markedly high risk for future cardiovascular morbidity and mortality has not been fully elucidated. We examined the associations between serum adiponectin and several biomarkers related to cardiovascular disease and heart failure in a large high-risk population comprising patients with prevalent CHD. Methods: We measured fasting adiponectin, interleukin-6 (IL-6), high-sensitivity C-reactive protein (hsCRP), N-terminal pro-B-type natriuretic peptide (NT-proBNP), and markers of lipoprotein metabolism in 1174 patients with CHD. Results: After adjustment for age and sex, adiponectin was associated with HDL-cholesterol (HDL-C; r = 0.25; P <0.0001), NT-proBNP (r = 0.17; P <0.0001), and plasma triglyceride (r = −0.21; P <0.0001) concentrations. There was, however, no statistically significant association between adiponectin and markers of systemic inflammation. In partial correlation analyses further adjusted for body mass index, alcohol intake, smoking status, presence of diabetes and/or hypertension, lipid-lowering drug therapy, and fasting plasma glucose, adiponectin remained significantly associated with HDL-C (r = 0.21; P <0.0001), NT-proBNP (r = 0.15; P <0.0001), and plasma triglycerides (r = −0.16; P <0.0001). Conclusions: Serum adiponectin is associated with the presence of atherogenic dyslipidemia and with NT-proBNP concentration but not with markers of systemic inflammation in patients with manifest CHD. Thus, atherogenic dyslipidemia may link adiponectin with the progression of atherosclerosis. Moreover, serum adiponectin may be related to BNP in patients with CHD.

Integrity signals

Registry

Crossref · 10.1373/clinchem.2005.060509

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A disparity in the inflammatory cytokine system occurs in obese individuals with heart failure: pro-inflammatory cytokines IL-6, IL-1β, ANP, and TNF-α increase, while anti-inflammatory cytokines IL-10 and TGF-β do not correspondingly increase.

    “It appears that a disparity in the inflammatory cytokine system occurs in obese individuals with heart failure since, while pro-inflammatory cytokines such as interleukin (IL)-6, IL-1β, atrial natriuretic peptide (ANP), and tumor necrosis factor (TNF)-α increase, there is not a corresponding increase in anti-inflammatory cytokines such as IL-10 and TGF-β (122, 366).”

    From Cardiac remodeling in obesity (2008) · cites this paper as [366]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
von Eynatten, M., Hamann, A., Twardella, D., Nawroth, P. P., Brenner, H., & Rothenbacher, D.
Affiliations
  • Department of Medicine I (Endocrinology and Metabolism), Ruprecht-Karls-University of Heidelberg, Heidelberg, Germany
  • Heidelberg University (DE)
  • Department of Epidemiology, German Centre for Research on Ageing, Heidelberg, Germany
Venue
Clinical Chemistry
Published
2006-05-01
Volume
52
Issue
5
Pages
853-859
ISSN
  • 0009-9147 (ISSN-L)
  • 1530-8561
OpenAlex
W2171233936
Cited by
140
References
35
Citations by year
2026: 1 · 2025: 3 · 2024: 1 · 2023: 3 · 2022: 2 · 2021: 5 · 2020: 5 · 2019: 1 · 2018: 5 · 2017: 8 · 2016: 4 · 2015: 7 · 2014: 10 · 2013: 6 · 2012: 8
FWCI
11.71
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Chemistry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
  • Health Sciences › Medicine › Physiology › Adipose Tissue and Metabolism
Keywords
adiponectin, coronary artery disease, atherogenic dyslipidemia, heart failure, NT-proBNP, systemic inflammation, interleukin-6, C-reactive protein, HDL cholesterol, triglycerides, lipoprotein metabolism, atherosclerosis progression
MeSH terms
Adult, Aged, Coronary Disease, Cross-Sectional Studies, Female, Heart Failure, Humans, Inflammation, Male, Middle Aged, Peptide Fragments, Risk Factors, Socioeconomic Factors, Biomarkers, Prevalence, Multivariate Analysis, Ventricular Function, Left, Natriuretic Peptide, Brain, Dyslipidemias, Atherosclerosis, Adiponectin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review